Navigation Links
CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
Date:11/3/2008

ward to further evaluating the correlation between rash and clinical activity, as well as alternate dosing schedules of CR011-vcMMAE," commented Dr. Hwu.

CuraGen is currently enrolling patients into a Phase I portion of this trial to evaluate more frequent dosing schedules of CR011-vcMMAE, including a weekly and a two out of every three-week regimen, to explore if more frequent administration can provide additional activity in patients with metastatic melanoma. CR011-vcMMAE is also being studied in an ongoing Phase II trial in patients with metastatic breast cancer who have received previous chemotherapy. CuraGen anticipates providing updated data from the ongoing melanoma and breast cancer studies in the first half of 2009.

"While we continue to finalize data from this study, develop data from more frequent dosing in patients with metastatic melanoma and from the Phase II study in patients with breast cancer, we will be engaging in discussions with potential partners as we develop plans for the advanced stages of development," added Dr. Shannon. "The goal of a partnership will be to support the financial, development and commercial resources that will be required in advanced development, improving the risk profile to CuraGen shareholders while maintaining upside potential."

In addition to M. D. Anderson, other sites participating in the melanoma trial include Yale Cancer Center, New Haven, CT; The Angeles Clinic and Research Institute, Santa Monica, CA; and New York University Medical Center, New York, NY.

Reprints of the presentation will be made available on CuraGen's website at http://www.curagen.com or can be requested by emailing info@curagen.com.

Conference Call Details and Dial-in Information

Date: Monday, November 3, 2008

Time: 11:00 a.m. EDT

Dial-in: 877-272-5391 (domestic)

706-758-4315 (international)

Passcode: 71190
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
10. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
11. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... CYBX ) today announced results for the quarter ended ... Operating results for the first quarter of fiscal ... other achievements, include: , Worldwide net product sales of ... net sales of $13.2 million, an increase of 14.5% on ... reached a new high of $58.8 million, an increase of ...
(Date:8/21/2014)... , Aug. 21, 2014   Auxilium Pharmaceuticals, ... specialty biopharmaceutical company, today announced positive results from ... clostridium histolyticum (or CCH) for the treatment of ... In the Phase 2a trial, all three doses ... (0.84mg)) showed an improvement in the appearance of ...
(Date:8/20/2014)... , Aug. 20, 2014  The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down meth offenders and make arrests. Data released ... Kentucky blocked the sale of more ...
Breaking Medicine Technology:Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Kentucky's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... genetics,(Nasdaq: DCGN ) today announced the filing ... the company,s novel small-molecule modulator,of phosphodiesterase 4 (PDE4), ... compound is being developed as a new and ... loss and cognitive deficits associated,with Alzheimer,s disease and ...
... from the,French Medicine Agency (AFSSAPS) the authorization to ... PL37, its lead compound for oral,treatment of neuropathic ... pain condition, with an estimated,prevalence in the world,s ... most,recent surveys, with many causes such as shingles, ...
Cached Medicine Technology:deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 2deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 3deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 4deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 5Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I 2
(Date:8/21/2014)... Chicago, IL (PRWEB) August 21, 2014 ... its 33rd annual Inc. 500|5000, an exclusive ranking of ... most comprehensive look at the most important segment of ... Timberland, Dell, Domino’s Pizza, LinkedIn, Zillow, and many other ... Inc. 500|5000. , “Centurion is proud to have been ...
(Date:8/21/2014)... MISSOULA, Mont. (PRWEB) August 21, 2014 She ... struck blind and brain injured after a surgery to correct ... “He Works All Things Together…” author Rebecca Strom-Stewart shares her ... misguided good intentions that led to a miscarriage of justice ... trudge through the tunnel of darkness and into the light,” ...
(Date:8/21/2014)... Raton, FL (PRWEB) August 21, 2014 Teen ... people in Boca Raton, FL. The rising numbers of young ... been staggering. To help make a difference in the community, ... provide a valuable resource for teens seeking to overcome something ... to help parents and their teens find the best teen ...
(Date:8/21/2014)... Charleston, SC (PRWEB) August 21, 2014 ... one of seven start-ups selected to participate in ... program provides entrepreneur mentorship, curriculum sessions and valuable ... scalable businesses in the region. Each start-up selected ... and support in order to help businesses grow ...
(Date:8/21/2014)... 21, 2014 InSilico Medicine, ... and addressing the challenges of a rapidly ... for signalome-wide pathway analysis. This new ... analysis of gene expression data obtained using ... in the journal Frontiers in Molecular Biosciences, ...
Breaking Medicine News(10 mins):Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 2Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 3Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 4Health News:The Dramatic, Uplifting Story from a Brain Injured Woman 2Health News:New Helpline Provides Hope for Troubled Teens in Boca Raton 2Health News:OncoFinder, a new algorithm for minimizing errors in high-throughput transcriptome analysis 2
... PUA Forums.com, the ... meet and charm women, is now also helping men take it to the next level - ... ... for dating advice that has already helped thousands of men learn how to meet and charm ...
... ... the rage. Today more than ever, people are turning to books on attaining success to ... lumped together, a recent discovery by Steve Paris, CEO of Orne Publishing, is about to turn ... , ...
... , ... days in June, QuickMedical® converted their 11,000 square foot warehouse into a showcase for ... of free food and prizes, the QuickMedical® Open House and Benefit was an event ... ...
... ... web portal that provides a comprehensive view of California public policy and legislative issues. ... tracking in one site. , ... (PRWEB) June 28, 2010 -- The ‘LegisWeb Eye’ launches on July 1st, bringing a new ...
... lower their cholesterol are 30 percent less likely to see ... who do not use the drugs, according to researchers at ... of the drugs were associated with lower risk of recurrence. ... "The findings add another layer of evidence ...
... , SUNDAY, June 27 (HealthDay News) -- Scientists have located ... predisposition for type 2 diabetes, bringing the total number of ... At this point, the findings don,t mean much for patients ... treatments. "From here, to apply this clinically is going ...
Cached Medicine News:Health News:PUA Forums Will Help You Get A Girlfriend 2Health News:Discovery of Napoleon Hill Book Bound to Change Fate for Millions 2Health News:Discovery of Napoleon Hill Book Bound to Change Fate for Millions 3Health News:QuickMedical Open House and Benefit for Seattle Children's Hospital A Resounding Success 2Health News:QuickMedical Open House and Benefit for Seattle Children's Hospital A Resounding Success 3Health News:The 'LegisWeb Eye' Legislative Web Portal Launches on July 1st 2Health News:The 'LegisWeb Eye' Legislative Web Portal Launches on July 1st 3Health News:Statins associated with lower cancer recurrence following prostatectomy 2Health News:More Genes Implicated in Type 2 Diabetes 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: